EMA scales back transparency initiatives because of workload
dc.contributor.author | Doshi, Peter | |
dc.date.accessioned | 2018-08-15T11:34:13Z | |
dc.date.available | 2018-08-15T11:34:13Z | |
dc.date.issued | 2018-08-14 | |
dc.identifier.citation | Doshi, P. (2018) EMA scales back transparency initiatives because of workload. BMJ. 362:k3513. DOI: 10.1136/bmj.k3513 | en_US |
dc.identifier.uri | http://hdl.handle.net/10713/8133 | |
dc.description | Peter Doshi discusses recent changes to two of the EMA’s policies affecting access to its archives (policy 0043) and publication of new clinical data (policy 0070). The former is a permanent revision while the latter is temporary. Both policies reduce transparency by restricting access to drug data critical to independent research initiatives associated with safety, efficacy, and appropriate trial methodology. | en_US |
dc.description.uri | http://bmj.com/cgi/content/full/bmj.k3513?ijkey=XAqxutYhD4TBabt&keytype=ref | en_US |
dc.language.iso | en_US | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | data access policies | en_US |
dc.subject | EMA | en_US |
dc.subject | policy 0043 | en_US |
dc.subject | policy 0070 | en_US |
dc.subject.lcsh | European Medicines Agency | en_US |
dc.subject.mesh | Access to Information | en_US |
dc.title | EMA scales back transparency initiatives because of workload | en_US |
dc.type | Article | en_US |
dc.description.uriname | Click here for free full-text article on publisher's website | en_US |
refterms.dateFOA | 2019-02-19T18:34:50Z |